Anti-tumour activity of low molecular weight heparin doxorubicin nanoparticles for histone H1 high-expressive prostate cancer PC-3M cells

Zhang, Shuang; Li, Zhantao; Liu, Man; Wang, Jingru; Xu, Meiqi; Li, Zhuoyue; Duan, Xiao-Chuan; Hao, Yanli; Zheng, Xiu-Chai; Li, Hui; Feng, Zhen-Han; Zhang, Xuan

doi:10.1016/j.jconrel.2018.12.034

Cited by 15 publications

(13 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous research, we synthesized low-molecular-weight heparin–doxorubicin complex (LMHP-DOX) and prepared LMHP-DOX NPs. Our results indicated that via histone H1 (H1)-mediated, LMHP-DOX NPs efficiently crossed the cell membrane, escaped the lysosomes, localized in the perinuclear region, produced DOX directly in the nucleus, and increased the concentration of DOX in the nucleus of H1 high-expressive PC-3M cells, enhancing the apoptotic activity of the cancer cells …”

Section: Introductionmentioning

confidence: 85%

See 1 more Smart Citation

Antitumor Activity of the Zinc Oxide Nanoparticles Coated with Low-Molecular-Weight Heparin and Doxorubicin Complex In Vitro and In Vivo

Zhang

Liu

et al. 2022

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Various metal oxide nanomaterials have been widely used as carriers to prepare pH-sensitive nanomedicines to respond to the acidic tumor microenvironment promoting antitumor efficiency. Herein, we used zinc oxide nanoparticles (ZnO NPs) as metal oxide nanomaterial coated with low-molecular-weight heparin (LMHP) and doxorubicin (DOX) complex (LMHP-DOX) to prepare ZnO-LD NPs for controllable pH-triggered DOX release on the targeted site. Our results indicated that the released DOX from ZnO-LD NPs was pH-sensitive. The oxygen produced by ZnO-LD NPs in H 2 O 2 solution was observed in in vitro experiment. The ZnO-LD NPs entered into both PC-3M and 4T1 tumor cells via clathrin-mediated endocytosis and micropinocytosis pathway. The intracellular reactive oxygen species (ROS) generated by ZnO-LD NPs could significantly increase the caspase 3/7 level, leading to tumor cell apoptosis. The in vitro and in vivo antitumor activity was confirmed in PC-3M and 4T1 cell lines or tumor-bearing mice models. The in vivo and in vitro tumor images via second-order nonlinearity of ZnO-LD NPs indicated that ZnO-LD NPs could penetrate deep into the tumor tissues. Therefore, the ZnO-LD NPs developed in our study could provide an efficient approach for the preparation of pH-sensitive nano delivery systems suitable for tumor therapy and imaging.

show abstract

Section: Introductionmentioning

confidence: 85%

“…ZnO NPs and LMHP-DOX complex were synthesized according to our previous report . The ZnO NPs, which dispersed in DMSO and the LMHP-DOX DMSO solution, were incubated overnight at room temperature, with stirring.…”

Section: Methodsmentioning

confidence: 99%

Antitumor Activity of the Zinc Oxide Nanoparticles Coated with Low-Molecular-Weight Heparin and Doxorubicin Complex In Vitro and In Vivo

Zhang

Liu

et al. 2022

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Generally, MCF-7 or MCF-7/ADR cells were seeded in 96-well plates at a density of 6 × 10 3 cells/well, and adhered at 37 °C for 24 h. Then, cells were exposed to increasing concentrations of NPs. After 48 h incubation, the culture medium was discarded, and the post-treatment method was the same as that in the previous study (Zhang et al, 2019 ).…”

Section: Methodsmentioning

confidence: 99%

Effect of XlogP and hansen solubility parameters on the prediction of small molecule modified docetaxel, doxorubicin and irinotecan conjugates forming stable nanoparticles

Zhong

Yao

et al. 2021

Drug Delivery

Self Cite

View full text Add to dashboard Cite

Small molecule-chemotherapeutic drug conjugate nanoparticles (SMCDC NPs) has a great advantage in improving drug loading. However, the factors which influence these conjugates forming stable nanoparticles (NPs) are currently unclear. In our previous studies, we synthesized a series of fatty acid-paclitaxel conjugates and suggested that the changes in the hydrophobic parameters (XlogP), solubility parameters and crystallinity of these fatty acid-paclitaxel conjugates were the key factors for affecting these small molecule-chemotherapeutic drug conjugates (SMCDCs) forming stable NPs in water. Here, we selected clinically widely used chemotherapeutic drug (docetaxel (DTX), doxorubicin (DOX) and irinotecan (Ir)) as model drug, and chose three straight-chain fatty acids (acetic acid (Ac), hexanoic acid (HA) and stearic acid (SA)) and one branched small molecule (N-(tert-butoxycarbonyl) glycine (B-G)) to synthesize 12 SMCDCs. Our results indicated that our prediction criterions obtained from paclitaxel conjugates were also appropriated for these synthesized SMCDCs. We suggested that the present studies expanded the scope of application of the above-mentioned influencing factors, provided research ideas for the rational design of SMCDC forming NPs and a basis for screening NPs with good anticancer activity.

show abstract

“…Myocardial injury caused by chemotherapy drugs is a major reason that affecting the prognosis of tumor patients ( Zhang et al, 2019 ). Statistically, 70% of patients in worldwide have different degrees of cardio-toxic reactions during chemotherapy, and these symptoms will accompany them for life ( Leemasawat et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

ELA-11 protects the heart against oxidative stress injury induced apoptosis through ERK/MAPK and PI3K/AKT signaling pathways

et al. 2022

View full text Add to dashboard Cite

Increasing evidence revealed that apoptosis and oxidative stress injury were associated with the pathophysiology of doxorubicin (DOX)-induced myocardial injury. ELABELA (ELA) is a newly identified peptide with 32 amino acids, can reduce hypertension with exogenous infusion. However, the effect of 11-residue furn-cleaved fragment (ELA-11) is still unclear. We first administrated ELA-11 in DOX-injured mice and measured the cardiac function and investigated the effect of ELA-11 in vivo. We found that ELA-11 alleviated heart injury induced by DOX and inhibited cardiac tissues from apoptosis. In vitro, ELA-11 regulated the sensitivity towards apoptosis induced by oxidative stress with DOX treatment through PI3K/AKT and ERK/MAPK signaling pathway. Similarly, ELA-11 inhibited oxidative stress-induced apoptosis in cobalt chloride (CoCl2)-injured cardiomyocytes. Moreover, ELA-11 protected cardiomyocyte by interacting with Apelin receptor (APJ) by using 4-oxo-6-((pyrimidin-2-ylthio) methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221). Hence, our results indicated a protective role of ELA-11 in oxidative stress-induced apoptosis in DOX-induced myocardial injury.

show abstract

Anti-tumour activity of low molecular weight heparin doxorubicin nanoparticles for histone H1 high-expressive prostate cancer PC-3M cells

Cited by 15 publications

References 66 publications

Antitumor Activity of the Zinc Oxide Nanoparticles Coated with Low-Molecular-Weight Heparin and Doxorubicin Complex In Vitro and In Vivo

Antitumor Activity of the Zinc Oxide Nanoparticles Coated with Low-Molecular-Weight Heparin and Doxorubicin Complex In Vitro and In Vivo

Effect of XlogP and hansen solubility parameters on the prediction of small molecule modified docetaxel, doxorubicin and irinotecan conjugates forming stable nanoparticles

ELA-11 protects the heart against oxidative stress injury induced apoptosis through ERK/MAPK and PI3K/AKT signaling pathways

Contact Info

Product

Resources

About